Table 1. Selected trials of agents targeting EGFR axis.
| Treatment line | Treatment | SqCLC patients/all patients | Outcome | P value | Reference |
|---|---|---|---|---|---|
| 1st | Cisplatin/gemcitabine +/− erlotinib | 482/1,172 | OS 10.8 mos (chemo plus erlotinib) vs. 11.0 mos (chemo alone) | 0.49 | (38) |
| 1st | Carboplatin/paclitaxel +/− erlotinib | 185/1,059 | OS 10.6 mos (erlotinib) vs. 10.5 mos (placebo) | 0.95 | (39) |
| 2nd–3rd | Vandetanib vs. erlotinib | 272/1,240 | PFS 2.6 mos (vandetanib) vs. 2.0 mos (erlotinib) | 0.721 | (40) |
| 2nd | Erlotinib + bevacizumab vs. erlotinib | 28/636 | OS 9.3 mos (erlotinib + bevacizumab) vs. 9.2 mos (erlotinib) | 0.7583 | (41) |
| 2nd | Docetaxel/pemetrexed vs. erlotinib | 154/304 | OS 5.5 mos (erlotinib) vs. 5.3 mos (chemotherapy) | 0.73 | (42) |
| 2nd–3rd | Sunitinib + erlotinib vs. erlotinib | 270/960 | OS 9.0 mos (sunitinib + erlotinib) vs. 8.5 mos (erlotinib) | 0.1388 | (43) |
| 2nd | Docetaxel vs. erlotinib in EGFR wild type | 54/222 | 8.2 mos (docetaxel) vs. 5.4 mos (erlotinib) | 0.05 | (44) |
| 1st | Cisplatin/gemcitabine +/− gefitinib | 327/1,093 | OS 9.9 mos (gefitinib 500 mg q day) vs. 9.9 mos (gefitinib 250 mg q day) vs. 10.9 mos (placebo) | 0.46 | (45) |
| 1st | Carboplatin/paclitaxel +/− gefitinib | 195/1,037 | OS 8.7 mos (gefitinib 500 mg q day) vs. 9.8 mos (gefitinib 250 mg q day) vs. 9.9 mos (placebo) | 0.64 | (46) |
| 2nd | Gefitinib vs. placebo | 586/1,692 | OS 5.6 mos (gefitinib) vs. 5.1 mos (placebo) | 0.09 | (47) |
| 2nd | Gefitinib vs. docetaxel | 361/1,466 | OS 7.6 mos (gefitinib) vs. 8.0 mos (docetaxel) | >0.05 | (48) |
| 1st | Cisplatin/vinorelbine +/− cetuximab (EGFR positive) | 377/1,125 | OS 11.3 mos (chemotherapy plus cetuximab) vs. 10.1 mos (chemotherapy alone) | 0.04 | (49) |
| 1st | Carboplatin/taxanes +/− cetuximab | 171/676 | PFS 4.4 mos (chemo plus cetuximab) vs. 4.2 mos (chemo alone) | 0.24 | (50) |
SqCLC, squamous cell lung cancer; EGFR, epidermal growth factor receptor; mos, months.